Dr. Daniel Faden is a board-certified specialist in head and neck cancer surgery. He earned his undergraduate degree from the University of Michigan and medical degree from Boston University School of Medicine, before completing residency training in otolaryngology–head and neck surgery at the University of California, San Francisco. He then pursued two clinical fellowships at the University of Pittsburgh Medical Center in advanced head and neck oncologic surgery and cranial base surgery.
Seeing patients at Boston Medical Center, Dr. Faden’s clinical practice focuses on providing comprehensive care for the entire spectrum of benign and malignant head and neck tumors, including oral cavity, oropharynx, larynx, endocrine (thyroid and parathyroid), cutaneous (skin), salivary, sinonasal, and cranial base neoplasms. He has a particular interest and expertise in minimally invasive head and neck cancer surgery (TORS, TOLS, endoscopic cranial base surgery), precision/personalized head and neck oncology, and the management of HPV-associated head and neck cancers. He emphasizes a multidisciplinary approach to patient care to optimize oncologic, functional, and cosmetic outcomes for complex patients.
Dr. Faden is an active head and neck cancer translational investigator. Prior to Mass. Eye and Ear, he was a Howard Hughes Medical Institute Research Scholar at the National Institutes of Health/National Human Genome Research Institute and completed a postdoctoral research fellowship at the University of Pittsburgh. His research focuses on how different cellular alterations, such as DNA mutations and infection by human papilloma virus, effect the behavior of head and neck cancers, with the goal of translating findings into advancements in precision head and neck oncology care.
Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. Li R, Faden DL, Fakhry C, Langelier C, Jiao Y, Wang Y, Wilkerson MD, Pedamallu CS, Old M, Lang J, Loyo M, Ahn SM, Tan M, Gooi Z, Chan J, Richmon J, Wood LD, Hruban RH, Bishop J, Westra WH, Chung CH, Califano J, Gourin CG, Bettegowda C, Meyerson M, Papadopoulos N, Kinzler KW, Vogelstein B, DeRisi JL, Koch WM, Agrawal N. Head Neck. 2015 Nov;37(11):1642–9.
Targeted next-generation sequencing of TP53 in oral tongue carcinoma from non-smokers. Faden DL, Arron ST, Heaton CM, DeRisi J, South AP, Wang SJ. J Otolaryngol Head Neck Surg. 2016 Sep 17;45(1):47.
Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. Faden DL, Algazi A. J Natl Cancer Inst. 2016 Sep 26;109(1).
Whole exome sequencing of growing and non-growing cutaneous neurofibromas from a single patient with Neurofibromatosis Type 1. Faden DL, Asthana S, Tihan T, DeRisi J, Kliot M. PLoS One. 2017 Jan 18;12(1):e0170348.
Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma. Faden DL, Thomas S, Cantalupo PG, Agrawal N, Myers J, DeRisi J. Oral Oncol. 2017 Nov;74:8–14.
View a complete list of publications on pubmed.gov »